Both BrM and GBM had a broad CD45+ leukocyte infiltrate, with a range between 5.3% and 63.9% among live cells (median 19.6%) for BrM and 14.4% and 72.9% for GBM (median 36.4%), as shown in Figure 1D. This evidence concerns the gene PTPRC and glioblastoma.